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Background: A large number of patients with bipolar disorder (BD) can be characterized by predominant polarity
(PP), which has important implications for relapse prevention. Recently, Popovic et al. (EUR NEUROPSYCHOPHARM
22(5): 339–346, 2012) proposed the Polarity Index (PI) as a helpful tool in the maintenance treatment of BD. As a
numeric expression, it reflects the efficacy of drugs used in treatment of BD. In the present retrospective study, we
aimed to validate this Index in a large and well characterized German bipolar sample.
Methods: We investigated 336 bipolar patients (BP) according to their PP and calculated the PI for each patient in
order to prove if maintenance treatment differs according to their PP. Furthermore, we analysed whether PP is
associated with demographic and clinical characteristics of BP.
Results: In our sample, 63.9% of patients fulfilled criteria of PP: 169 patients were classified as depressive
predominant polarity (DPP), 46 patients as manic predominant polarity (MPP). The two groups differed significantly
in their drug regime: Patients with DPP were more often medicated with lamotrigine and antidepressants, patients
with MPP were more often treated with lithium, valproate, carbamazepine and first generation antipsychotics.
However, patients with DPP and MPP did not differ significantly with respect to the PI, although they received
evidence-based and guideline-driven treatment.
Conclusion: The reason for this negative finding might well be that for several drugs, which were used frequently,
no PI value is available. Nevertheless we suggest PP as an important concept in the planning of BD maintenance
treatment.
Keywords: Bipolar disorder, Predominant polarity, Polarity index, Maintenance treatment, Depression, Mania, EBMBackground
In spite of advances in evidence-based drug treatment,
bipolar disorder (BD) remains an often recurrent illness
causing severe impairments in patients’ daily life. Thus,
relapse prevention is the main objective in treatment
strategies of BD. Regarding the drug regimen in BD, a
patient’s actual symptomatology plays a crucial role.
However, for maintenance treatment the individual ill-
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unless otherwise stated.drug responders) must be considered. Residual symp-
toms, psychiatric comorbidity, and number of prior epi-
sodes have been identified as risk factors of recurrence
[1]. Additionally, the polarity of the first mood episode
seems to be a good predictor of the predominant polar-
ity of subsequent episodes over time [2], i.e. an overall
higher number of depressive episodes is observed in pa-
tients with first episode depression and vice versa, and
thus should be taken into account in treatment planning.
The categorization of bipolar disorder patients (BP)
according to predominant polarity might help to optimize
relapse prevention. Patients with a depressive predomin-
ant polarity (DPP) have a higher risk of further depressive
episodes in the future and therefore need a treatmentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tients with manic or hypomanic predominant polarity
(MPP) require a drug regimen specifically efficient in the
prevention of mania. For example, antidepressants should
be avoided in patients with MPP due to the risk of trigger-
ing manic symptoms [3]. However, not every BP has a
clear tendency for one pole of the disorder. Recent re-
search reported that a clear predominant polarity can be
observed in roughly half of BP, and that DPP is more
prevalent than MPP [4,5].
Several disease specific variables have been associated
with the concept of predominant polarity [5,6]. For in-
stance, it has been demonstrated that depressive polarity
coincides with a worse prognosis and decreased treat-
ment response compared to manic polarity [7,8]. Fur-
thermore, the later patients with DPP, often initially
misdiagnosed as patients suffering from major depres-
sion (“hidden bipolars”), receive a correct diagnosis (and
an adequate drug treatment, accordingly), the more se-
vere the course of illness [5,9], i.e. patients with DPP are
at a higher risk for misdiagnosis and subsequent worse
prognosis. Thus, subtyping of BD by using the concept
of predominant polarity could improve the planning of
clinical care, long-term prevention, and the development
of new therapeutic strategies. Furthermore, more homo-
geneous subgroups might provide the potential to in-
form biological studies and the search for biomarkers.
Therefore, mechanisms involved in the pathophysiology
of BD could be studied in a more target-oriented fash-
ion. However, up to now there are no genetic, familial
or biomarker studies on predominant polarity in BD, and
the biological underpinnings remain unknown. Treatment
guidelines refer to the concept of predominant polarity
[10], and some authors even suggest that diagnostic cri-
teria of BD should include predominant polarity as a rele-
vant course descriptor for the illness [11,12]. However, the
recently published DSM-5 [13] did not add predominant
polarity as a course specifier.
Recently, the idea of predominant polarity in BD was
introduced as a helpful tool for maintenance treatment.
Popovic et al. [14] proposed the Polarity Index (PI) as a
descriptor for categorizing drug profiles in the relapse
prevention of BD. The Polarity Index is a numeric ex-
pression of the efficacy profile of a given drug, derived
from the ratio of Numbers Needed to Treat (NNT) for
the prevention of depression and NNT for the preven-
tion of mania. The NNT expresses the reciprocal of the
absolute risk reduction and is calculated based on the
results of several randomized placebo-controlled trials
[14]. According to the authors, a PI of 1 indicates equal
efficacy of a drug in the prevention of manic and depres-
sive episodes alike. Drugs with a PI >1 have a stronger
anti-manic prophylactic effect, while drugs with an
index <1 are more efficient in preventing depressiveepisodes. In a second study, Popovic et al. provided evi-
dence for the validity of the index in a large sample of
BP by calculating a PI value for each patient [15]. They
demonstrated that the mean PI values in their bipolar
sample were significantly higher in patients with MPP
compared to patients with DPP, indicating a stronger
antimanic treatment regimen in MPP. The treatment of
patients with DPP was characterized by lower mean PI,
indicating a better prevention of depressive episodes.
Therefore, the authors suggested the PI as a useful numer-
ical expression of evidence-based maintenance treatment
in BD and recommended it as a simple concept for physi-
cians, one that is easily remembered and translatable into
clinical practice.
Up to now, most studies on predominant polarity were
performed by the Barcelona Bipolar Disorder Group
[14-17]. Therefore, the aim of the present study was to
validate the PI in a clinical setting with a similar study
design in a German sample. To do so, we aimed to repli-
cate the results by Popovic et al. by examining a well-
characterized bipolar sample in order to determine the
role of PI in clinical decision-making regarding mainten-
ance treatment in BD [15]. Furthermore, we were inter-
ested in associations between demographic or clinical
characteristics and predominant polarity in BP.
Methods
Sample
All patients were recruited in the context of the Bipolar
Disorder Program at the Department of Psychiatry,
Psychosomatics and Psychotherapy, University Hospital
Wuerzburg. The program provides multidisciplinary treat-
ment (inpatient and outpatient) for BP from Southern
Germany. Since the program started in 2009, a database
has been built and allows a prospective follow-up of
clinical and sociodemographic variables. Up to now,
464 BP have been phenotyped. Inclusion criterion for
the database was a diagnosis of bipolar subtype I or II
according to DSM-IV TR [18] criteria. Diagnosis was
confirmed by application of the Structured Clinical
Interview (SCID-I) [19] for DSM-IV and a consensus
diagnosis of two psychiatrists. Several clinical variables
were obtained from interviews with patients and their
relatives, as well as clinical records, including diag-
nosis BD type, number of previous episodes (depres-
sive, manic, and mixed), age of illness onset, polarity of
first episode, lifetime history of psychotic symptoms,
former attempted suicide, rapid cycling, and psychi-
atric comorbidities [attention deficit hyperactivity
disorder (ADHD), substance abuse, panic disorder,
migraine]. Furthermore, family history of psychiatric
disoders and treatment variables [medication, electro-
convulsive therapy (ECT)] were assessed. In addition,
patients’ life time psychopathological symptoms were
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Criteria Checklist for Psychotic and Affective Illness
(OPCRIT) [20]. All patients provided written informed
consent for the collection of their data for research,
participation in studies, and subsequent publication.
All procedures followed the Declaration of Helsinki in
its latest version and were approved by the Ethical
Committee of the medical faculty of the University of
Wuerzburg.
For the present study, the data of 336 BP (aged 18-74
years, 202 women and 134 men) with a diagnosis of
BD-I or BD-II were included in the analysis. The
remaining 128 patients in the database could not be an-
alyzed due to unreliable information about number of
previous episodes. Predominant polarity was defined in
accordance with previous studies [4,14]: MPP was char-
acterized by at least two-thirds of past episodes com-
plying with DSM-IV criteria for manic/hypomanic
episodes, and DPP was defined by at least two-thirds of
a patient’s past episodes fulfilling DSM-IV criteria for
Major Depressive Episode. Undetermined predominant
polarity (UPP) describes cases that did not fall into ei-
ther category [8]. Mixed episodes were recorded as well
but were not considered and assigned as a part of depres-
sive or manic polarity. In our sample only six patients had
twice as many mixed episodes than depressed and (hypo-)
manic episodes. Therefore we did not include a type of
predominant mixed polarity in our analyses.Polarity index
In order to calculate the PI, the current treatment of
each patient was used, irrespective of prescribed dos-
age. According to Popovic et al. [14], the PI values of
each drug for maintenance treatment were as follows:
12.09 for risperidone, 4.38 for aripiprazole, 3.91 for
ziprasidone, 2.98 for olanzapine, 1.39 for lithium, 1.14
for quetiapine, and 0.40 for lamotrigine. In the case of
polypharmacy, a value for each patient’s treatment was
calculated as the mean value of all prescribed drugs
combined. For instance, a patient treated with lithium
and quetiapine is characterized by a PI of 1.265 [1.39
(PI for lithium) +1.14 (PI for quetiapine)/2 (number of
drugs) =1.265]. Unfortunately, PI values are not avail-
able for all drugs used in relapse prevention of BD.
Most noteworthy, no PI was assigned to valproate and
carbamazepine as Popovic et al. [14] could not con-
duct NNT analyses due to lack of respective random-
ized controlled trials (RCTs). In conformity with the
validation study, these drugs were therefore not in-
cluded in our analyses [15]. Aside from the total PI,
we calculated separate PIs for antipsychotics (quetia-
pine, aripiprazole, risperidone, olanzapine, ziprasi-
done) and mood stabilizers (lithium, lamotrigine).Statistical analysis
For statistical analysis of the data, we used the Statis-
tical Package for Social Sciences (SPSS Inc., Chicago,
Illinois, USA) software for Windows (version 21). Demo-
graphic, clinical, and treatment variables of the three
groups (DPP, MPP and UPP) were compared using Chi
Square Tests (categorical variables) or ANOVAs (continu-
ous variables). All statistics were two-tailed. Bonferroni
correction for multiple testing was applied. Since the
Kolmogorov-Smirnov Test indicated no normal distribu-
tion of the data, Mann-Whitney-U-Test was used to
analyze differences in mean PI between the two groups
DPP and MPP. In order to ensure comparability with the
original study [15], we omitted the UPP group from this
analysis.
Results
Differences in clinical characteristics of BP with
predominant polarity
Our sample consisted of 336 BP with diagnosis type BP I
or II. 215 (63.9%) fulfilled the criteria of one predomin-
ant polarity (MPP or DPP). The remaining 121 (36.1%)
BP with undetermined predominant polarity (UPP) were
also included in the analysis. Within the predominant
polarity sample, 169 (78.6%) patients were classified as
DPP and 46 (21.4%) as MPP. Demographic and clinical
characteristics of the sample are shown in Table 1.
We compared the demographic and clinical parame-
ters between the two groups DPP and MPP in order to
detect differences between BP with regard to their pre-
dominant polarity. After Bonferroni correction for mul-
tiple testing, we found that patients with MPP had
significantly more often a diagnosis of BD-Type I
(p < .000), while in the DPP group both subtypes were
distributed equally. Irritability during mania was signifi-
cantly more prevalent in patients with MPP (p < .000).
Patients with MPP more often had a first episode of
mania at illness onset (p < .000), and patients classified
as MPP were younger when experiencing their first
(hypo-) manic episode (p = .001), compared to patients
with DPP. Psychotic symptoms were more prevalent in
MPP (p = .013), and females were more often classified
as DPP, while MPP was equally distributed in women
and men (p = .019). However, due to Bonferroni correc-
tion both group differences did not reach significance.
Polarity index and pharmacological treatment
Mann-Whitney-U-Tests were used to compare the PI of
DPP and MPP (Table 2). No significant difference in
total PI between DPP and MPP was observed. However,
the PI of mood stabilizers was lower in patients with
DPP compared to patients with MPP (p = .024), indicat-
ing a stronger antidepressant regimen in the DPP group.
There was no difference in the PI of antipsychotics
Table 1 Demographic and clinical characteristics of the bipolar sample according to predominant polarity
DPP (N = 169) MPP (N = 46) Chi Square padj
2
N (50.3%) N (13.7%)
Sex 5.49 .019
Female 116 (68.6) 23 (50)
Male 53 (31.4) 23 (50)
Subtype 31.45 <.000*
Bipolar I 80 (47.3) 43 (93.5)
Bipolar II 89 (52.7) 3 (6.5)
Family history of psychiatric disorders 138 (81.7) 35 (76.1) 0.71 .398
Family history of suicide 59 (34.9) 12 (26.1) 1.27 .259
Rapid cycling 19 (11.2) 3 (6.5) 0.88 .349
Psychotic symptoms 22 (13.0) 13 (28.3) 6.16 .013
First Episode Mania 11 (6.5) 30 (65.2) 80.75 <.000*
Mania with irritable mood 52 (30.8) 34 (73.9) 28.04 <.000*
Mixed Episodes 55 (34.6) 16 (39.0) 0.28 .597
Suicide attempts (life time) 68 (40.2) 15 (32.6) 0.89 .346
Substance abuse (life time) 18 (10.7) 10 (21.7) 3.93 .481
Treatment
Lithium 74 (43.8) 30 (65.2) 6.65 .010
Other Mood Stabilizers1 63 (37.3) 26 (56.5) 5.52 .019
Antipsychotics (incl. quetiapine) 117 (69.2) 43 (93.5) 11.17 .001*
Antidepressants 121 (71.6) 14 (30.4) 26.22 <.000*
Mean (SD) Mean (SD) t padj.
2
Age 50.3 (14.8) 52.1 (12.2) -.765 .451
Age of Onset 29.8 (11.8) 28.5 (10.4) .667 .505
Age of first depression 29.7 (12.1) 31.6 (12.1) -0.85 .396
Age of first mania 37.1 (14.5) 28.8 (11.0) 3.43 .001*
Duration of illness 20.5 (12.5) 23.6 (12.6) -1.45 .148
Total number of episodes 11.1 (10.2) 10.7 (6.3) 0.282 .778
Number of manic episodes 2.3 (2.5) 8.3 (5.5) -10.56 <.000*
Number of depressive episodes 8.6 (8.0) 2.4 (2.0) 5.26 <.000*
Number of mixed episodes 1.0 (2.8) 0.71 (1.2) .736 .463
*p< .05.
DPP = depressive predominant polarity, MPP =manic predominant polarity, UPP = uncertain predominant polarity.
1(Valproate, Lamotrigine, Carbamazepine, Oxcarbazepine).
2We used bonferroni correction for multiple testing (23 hypotheses) for adjusting the p-values to 0.0022 (0.05/23).
Table 2 Mean Values and tests of differences of Polarity Indices in predominant polarity groups
DPP MPP Kolmogorov-
Smirnov Z
p Mann-Whitney
U-Test
p
(N = 169) (N = 46)
Mean (SD) Mean (SD)
Total Polarity Index 1.95 (0.20) 2.17 (0.37) 5.947 .000*** 3579.5 .407
Polarity Index AP 1.87 (0.23) 2.20 (0.52) 6.091 .000*** 388.5 .997
Polarity Index MS 0.63 (0.50) 0.89 (0.96) 5.733 .000*** 3118.5 .024*
*p< .05.
***p< .001.
DPP = depressive predominant polarity, MPP =manic predominant polarity, UPP = uncertain predominant polarity, AP = Antipsychotics, MS =Mood Stabilizers.
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proat and carbamazepine available, we conducted a
subset analyses by excluding those patients treated
with one of these mood stabilizers. However, again we
found no significant difference in the total PI (p = .810), PI
of mood stabilizers (p = .658) and PI of antipsychotics
(p = .238) between DPP and MPP.
The pharmacological treatment of BP is given in de-
tail in Table 3. Approximately half of the total sample
was treated with lithium. Between groups, patients with
MPP were more often medicated with lithium com-
pared to patients with DPP or UPP. Furthermore, our
results show that more patients with MPP were medi-
cated with valproate compared to patients with DPP or
UPP. However, these differences did not reach statis-
tical significance after correction for multiple testing.
15.5% of the total bipolar sample were treated with first
generation antispychotics (FGA), while second generationTable 3 Frequency of prescribed drugs in the bipolar sample
N total = 336 DPP
(100%) N = 169
(50%)
Mood Stabilizers
Lithium 165 (49.1) 74 (43.8)
Carbamazepine 10 (3.0) 2 (1.2)
Lamotrigine 32 (9.5) 22 (13.0)
Valproate 100 (29.8) 38 (22.5)
Topiramate 0 (0.0) 0 (0.0)
FGA 52 (15.5) 16 (9.5)
SGA 226 (67.3) 109 (64.5)
Quetiapine 138 (41.1) 70 (41.4)
Aripiprazole 38 (11.3) 22 (13.0)
Clozapine 18 (5.4) 5 (3.0)
Risperidone 40 (11.9) 13 (7.7)
Olanzapine 21 (6.3) 14 (8.3)
Ziprasidone 1 (0.3) 1 (0.6)
Pregabalin 17 (5.1) 8 (4.7)
Antidepressants 198 (58.9) 121 (71.6)
TCAs 91 (27.1) 56 (33.1)
IMAOs 3 (0.9) 3 (1.8)
SSRIs 32 (9.5) 17 (10.1)
SNRIs 75 (22.3) 49 (29.0)
Other 11 (3.3) 6 (3.6)
Polypharmacy (total) 170 (50.6) 94 (55.6)
Lithium + other MS 46 (13.7%) 17 (10.1%)
Lithium + SGAs 119 (35.5%) 48 (28.4%)
*p< .05.
DPP = depressive predominant polarity, MPP =manic predominant polarity, UPP = u
MS =Mood Stabilizer, FGA = first generation antipsychotics, SGA = second generatio
1We used bonferroni correction for multiple testing (20 hypotheses) for adjusting thantipsychotics (SGA) were prescribed in 67.3% of all BP.
Here, quetiapine was most commonly used. More than
half of the total bipolar sample (58.9%) was medicated
with antidepressants as add-on therapy, of which tricyclics
and selective noradrenalin reuptake inhibitors (SNRIs)
were most commonly used. 71.6% of patients with DPP
were treated with mood stabilizers and antidepressants,
compared to 30.4% of patients with MPP. Overall, 170 pa-
tients (50.6%) received polytherapy, distribution of which
did not differ between the three groups. Patients with
MPP significantly more often received a combination of
lithium and another mood stabilizer (p < .000), or a com-
bination of lithium and second generation antipsychotics,
compared to patients with DPP and UPP (p < .000).
Discussion
In the present study we investigated a sample of 336 BP
with regard to their predominant polarity, which isMPP UPP Chi
Square
padj
1
N = 46 N = 121
(14%) (36%)
30 (65.2) 61 (50.4) 6.77 .034
4 (8.7) 4 (3.3) 7.14 .028
3 (6.5) 7 (5.8) 4.84 .089
19 (41.3) 43 (35.5) 9.14 .010
0 (0.0) 0 (0.0) - -
15 (32.6) 21 (17.4) 15.31 <.000*
33 (71.7) 84 (69.4) 1.26 .532
21 (45.7) 47 (38.8) .66 .721
2 (4.3) 14 (11.6) 2.72 .256
4 (8.7) 9 (7.4) 3.96 .138
7 (15.2) 20 (16.5) 5.81 .055
2 (4.3) 5 (4.1) 2.40 .301
0 (0.0) 0 (0.0) 0.99 .609
1 (2.2) 8 (6.6) 1.44 .486
14 (30.4) 63 (52.1) 28.99 <.000*
5 (10.9) 30 (24.8) 9.58 .008
0 (0.0) 0 (0.0) 2.99 .224
2 (4.3) 13 (10.7) 1.70 .428
3 (6.5) 23 (19.0) 11.73 .003
1 (2.2) 4 (3.3) 0.217 .897
23 (50) 53 (43.8) 3.94 .139
16 (34.8%) 13 (10.8%) 19.98 <.000*
28 (60.9%) 43 (35.8%) 16.64 <.000*
ndetermined predominant polarity.
n antipsychotics, MAOs =Monoamine Oxidase Inhibitor.
e p-values to 0.0025 (0.05/20).
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one pole over the other. We aimed to identify clinical
characteristics associated with predominant polarity. Fur-
thermore, we attempted to validate the recently published
Polarity Index [14], a metric algorithm which expresses
the efficacy profile of a given drug in the maintenance
treatment of BD.
Approximately half of our sample was classified as
predominantly depressive (50.3%), 13.7% of patients as
predominantly manic, and 36% of patients had no de-
fined polarity. We found that the diagnosis type BP-I
was more prevalent in patients with MPP compared to
patients with DPP. These findings are in line with previ-
ous studies about predominant polarity and polarity of
first episode [4], given that patients with a manic episode
at illness onset more often receive the diagnosis type
BP-I [2]. A recent follow-up study by Gonzalez-Pinto
et al. [7] demonstrated that patients with DPP overall
had more episodes, more hospitalizations, and more sui-
cide attempts. However, we found no significant differ-
ences in number of previous episodes and suicidality
between the three groups. At onset of illness, manic epi-
sodes were more frequent in patients classified with
MPP compared to patients with DPP. This result, again,
is in line with previous work demonstrating that polarity
of first episode predicts the polarity of subsequent epi-
sodes over time [21,22]. In addition, patients with MPP
were significantly younger when experiencing their first
manic episode compared to patients classified as DPP.
In line with previous studies, our results show that DPP
was more prevalent in women, while MPP was equally
distributed in women and men [5,23]. Regarding family
history of psychiatric disorders, the literature showed an
association with DPP [7], however we could not confirm
this finding in our sample.
Regarding the Polarity Index, we could not replicate
the results by Popovic et al. [15]. In our sample, the PI
of maintenance treatment did not differ significantly
between patients with DPP and MPP. Therefore, we
could not validate the Polarity Index as a numeric ex-
pression of the efficacy of maintenance treatment under
naturalistic conditions. Only when mood stabilizers
(lithium and lamotrigine) were considered separately
were we able to detect a difference: Patients with DPP
had a lower PI of mood stabilizers compared to patients
with MPP. Furthermore, patients with DPP were treated
significantly more often with lamotrigine and antidepres-
sants than patients with MPP. In turn, lithium, valproate,
carbamazepine, risperidone and FGAs were more fre-
quently prescribed in MPP compared to DPP. Hence, our
bipolar sample received an evidence-based treatment for
relapse prevention, supported by pertinent guidelines such
as those published by the German Association for Psych-
iatry, Psychotherapy and Psychosomatics (DGPPN) [24]or the Canadian Network for Mood and Anxiety Treat-
ments [25]. It is therefore possible that the difference in
results may be due to different prescription patterns in the
present sample than in the Spanish sample. In our sample,
valproate, quetiapine, and aripiprazole were prescribed
considerably more often than in the study by Popovic
et al. [15]. In contrast, risperidone, olanzapine, and carba-
mazepine, which are often used in maintenance treatment
by the Spanish colleagues, were rarely prescribed in our
sample. Furthermore, antidepressants as add-on therapy
were administered more often in our sample. Due to the
naturalistic study design, our study sample also differed in
sociodemographic and clinical parameters from the sam-
ple of Popovic et al. [15]. For instance, diagnosis type
BP-II was overrepresented in our sample. Additionally, the
Spanish sample consisted of 44.4% of patients classified as
MPP, compared to only 21.4% in our sample. Therefore,
despite using a similar study design, different sample char-
acteristics and prescription patterns may be attributable
for the divergent results in our German sample.
A further factor hindering validation might be that no
PI was assigned to valproate due to missing RCTs. In-
deed, 30% of our patients were medicated with valproate,
compared to only 17% in the sample of Popovic et al.
[15]. The exclusion of a compound used in almost a
third of the patients therefore might have distorted our
results. In a similar vein, antidepressants do not have a
PI either, despite playing an undervalued role in the
maintenance treatment of BD [26], and consequently
were not considered in the present analysis. Moreover,
psychosocial interventions were also not considered for
analysis because information was not available about
how many patients of our sample received psychoeduca-
tion or psychotherapy in the past. As Popovic et al. [17]
demonstrated, psychosocial interventions differ in their
depression- or mania-preventive effects and can be eval-
uated by the PI. We therefore conclude that the unavail-
ability of a PI for several frequently used compounds in
maintenance treatment in BD might account for our
non-validation. Since we still consider the PI a clinically
useful measure, an effort should be made to assign a PI
to all substances used in the treatment of BD. In the per-
spective of evidence-based medicine, the PI could act in
addition to clinical interviews to provide a high standard
of patient care.
However, the PI has some general limitations which
should be considered. First of all, the index does not re-
flect pharmacodynamic interactions in the case of poly-
pharmacy, as it is only the numeric mean of the PIs of
the individual drugs, regardless of their dosage or pos-
sible interactions. Furthermore, the PIs of drugs used in
maintenance treatment are calculated according to
current available RCT studies. Up to now, well-designed
RCTs are rare, especially for mood stabilizers like valproate
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tinuous change with each new study. Other open questions
concern the maintenance treatment of patients without
predominant polarity (in the present sample, 36%), treat-
ment of first-episode patients, and how mixed states should
be classified. Furthermore, sub-syndromal depressive symp-
toms, which are prevalent during remission in BD, are not
taken into account in the classification of predominant po-
larity [6]. Despite these methodological shortcomings, the
idea of assigning a PI to a given drug and following rule-
based treatment upon the predominant polarity seems
reasonable and worthwhile; although we assume that
psychiatrists follow these rules intuitively, a formal descrip-
tion bears advantages especially for education purposes.
The present study design also has methodological limi-
tations. Our data consisted of retrospective self-reports
on previous episodes from BP, their relatives, and clinical
data. These are partially subjective, thus reducing the re-
liability of the data. Especially hypomanic episodes are
often not remembered well or tend to be misinterpreted
by patients. Furthermore, the subgroup of patients with
MPP was relatively small, which could explain the ab-
sence of statistical differences in PI values between pa-
tients with DPP and MPP.
Conclusions
To summarize, we found that predominant polarity was
associated with several clinical variables like sex, diagno-
sis subtype, irritability during mania, polarity at illness
onset and age of onset. However, we could not validate
the Polarity Index suggested by Popovic et al. [15] in
our bipolar sample. Despite evidence of different treat-
ment strategies in patients with depressive or manic pre-
dominant polarity, we found no significant differences in
PI values. Nevertheless, psychopharmacological strategies
must be adapted to the most frequently observed polar-
ity. The reason for the negative finding in this study
might well be that for some frequently used drugs in
maintenance treatment of BD no PI value is available.
Furthermore, we had different sample characteristics
and prescription patterns compared to Popovic et al.
[15]. Therefore, despite the failed validation of the PI in
our sample, we suggest the PI as a helpful orientation
in decision-making of maintenance treatment.
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